Commonwealth of Pennsylvania Public School Empls Retrmt SYS Takes Position in Indivior PLC $INDV

Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Indivior PLC (NASDAQ:INDV) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 57,977 shares of the company’s stock, valued at approximately $855,000.

Other large investors also recently bought and sold shares of the company. New York State Common Retirement Fund purchased a new position in shares of Indivior in the first quarter worth $295,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Indivior in the 1st quarter valued at $207,000. XTX Topco Ltd raised its stake in Indivior by 123.9% in the 1st quarter. XTX Topco Ltd now owns 50,437 shares of the company’s stock worth $481,000 after acquiring an additional 27,906 shares during the last quarter. Vanguard Group Inc. lifted its position in Indivior by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 4,631,221 shares of the company’s stock worth $43,765,000 after acquiring an additional 71,539 shares during the period. Finally, Nuveen LLC acquired a new stake in Indivior during the 1st quarter worth about $793,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Trading Up 3.1%

Indivior stock opened at $32.75 on Monday. The firm has a market cap of $4.52 billion, a PE ratio of 52.82 and a beta of 0.68. Indivior PLC has a 12 month low of $7.62 and a 12 month high of $33.30. The stock’s 50 day simple moving average is $26.37 and its two-hundred day simple moving average is $20.45.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, October 30th. The company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.34. The firm had revenue of $314.00 million during the quarter, compared to analysts’ expectations of $257.66 million. Indivior had a net margin of 6.65% and a negative return on equity of 86.28%. Indivior has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Indivior PLC will post 1.22 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on INDV. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 3rd. Northland Securities set a $40.00 price target on shares of Indivior in a report on Friday, October 31st. HC Wainwright lifted their price objective on shares of Indivior from $28.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $41.00 price objective (up from $27.00) on shares of Indivior in a report on Friday, October 31st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Indivior in a report on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Indivior presently has a consensus rating of “Buy” and a consensus target price of $32.17.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.